Cellceutix Corp.
Developing a still-secret prodrug for psoriasis, and a heralded cancer candidate
This article was originally published in Start Up
Executive Summary
These days, most start-up companies intent on developing a novel treatment for nearly any disease make a point of talking about their drug candidate’s presumed mechanism of action. It is pretty much de rigueur that a would-be drugmaker will discuss molecular something: if not the candidate itself, then certainly its target. But Cellceutix Corp. is not a typical start-up. Founded in June 2007, it became a publicly traded company through a reverse merger in December of that year. While the company appreciates the buzz that its anti-cancer candidate is generating, it is being a bit more tight-lipped about Prurisol, its novel drug candidate for psoriasis.
You may also be interested in...
Cellceutix Buys Mid-Stage Antibiotic Brilacidin On The Cheap
With brilacidin developer PolyMedix having filed for bankruptcy, Cellceutix will acquire the company’s assets for $2.1 million in cash and 1.4 million shares of stock.
New Orals, Better Topicals Top Psoriasis Wish List
Biologics for psoriasis leapfrogged existing treatments in the last decade, greatly improving the standard of care. Although those may still see incremental improvements, the real changes for patient care may come with the introduction of new oral and topical treatments. START-UP profiles four emerging companies that are tackling this challenge: Avexxin, Cellceutix, Creabilis, and Convoy Therapeutics.
Super-Specialist CROs: Commercializing Pharma R&D Expertise
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.